# An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer

> **NCT06883552** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sichuan University** · enrollment: 21 (estimated)

## Conditions studied

- Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Tislelizumab Injection

## Key facts

- **NCT ID:** NCT06883552
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2026-10-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06883552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06883552, "An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06883552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*